276 related articles for article (PubMed ID: 29032737)
1. Melanoma: a prototype of cancer-testis antigen-expressing malignancies.
Faramarzi S; Ghafouri-Fard S
Immunotherapy; 2017 Oct; 9(13):1103-1113. PubMed ID: 29032737
[TBL] [Abstract][Full Text] [Related]
2. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck.
Veit JA; Heine D; Thierauf J; Lennerz J; Shetty S; Schuler PJ; Whiteside T; Beutner D; Meyer M; Grünewald I; Ritter G; Gnjatic S; Sikora AG; Hoffmann TK; Laban S
Head Neck; 2016 Jul; 38(7):1008-16. PubMed ID: 26874246
[TBL] [Abstract][Full Text] [Related]
3. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
Park TS; Groh EM; Patel K; Kerkar SP; Lee CC; Rosenberg SA
J Immunother; 2016 Jan; 39(1):1-7. PubMed ID: 26641256
[TBL] [Abstract][Full Text] [Related]
4. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
5. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck.
Prasad ML; Jungbluth AA; Patel SG; Iversen K; Hoshaw-Woodard S; Busam KJ
Head Neck; 2004 Dec; 26(12):1053-7. PubMed ID: 15515159
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS
Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145
[TBL] [Abstract][Full Text] [Related]
8. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
Bodey B
Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
[TBL] [Abstract][Full Text] [Related]
9. Expression of cancer/testis antigens in cutaneous melanoma: a systematic review.
Tio D; Kasiem FR; Willemsen M; van Doorn R; van der Werf N; Hoekzema R; Luiten RM; Bekkenk MW
Melanoma Res; 2019 Aug; 29(4):349-357. PubMed ID: 30615012
[TBL] [Abstract][Full Text] [Related]
10. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy.
Zhang Y; Zhang Y; Zhang L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):281-291. PubMed ID: 30656409
[TBL] [Abstract][Full Text] [Related]
11. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
13. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma.
Errington JA; Conway RM; Walsh-Conway N; Browning J; Freyer C; Cebon J; Madigan MC
Br J Ophthalmol; 2012 Mar; 96(3):451-8. PubMed ID: 22190731
[TBL] [Abstract][Full Text] [Related]
14. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Tessari A; Pilla L; Silvia D; Duca M; Paolini B; Carcangiu ML; Mariani L; de Braud FG; Cresta S
Breast; 2018 Dec; 42():68-73. PubMed ID: 30189381
[TBL] [Abstract][Full Text] [Related]
15. Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy.
Gordeeva O
Semin Cancer Biol; 2018 Dec; 53():75-89. PubMed ID: 30171980
[TBL] [Abstract][Full Text] [Related]
16. Lack of XAGE-1b and NY-ESO-1 in metastatic lymph nodes may predict the potential survival of stage III melanoma patients.
Mori M; Funakoshi T; Kameyama K; Kawakami Y; Sato E; Nakayama E; Amagai M; Tanese K
J Dermatol; 2017 Jun; 44(6):671-680. PubMed ID: 28105694
[TBL] [Abstract][Full Text] [Related]
17. Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application.
Wei R; Dean DC; Thanindratarn P; Hornicek FJ; Guo W; Duan Z
Cancer Lett; 2020 Jun; 479():54-60. PubMed ID: 31634526
[TBL] [Abstract][Full Text] [Related]
18. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
19. NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis.
Smith SM; Iwenofu OH
Chin Clin Oncol; 2018 Aug; 7(4):44. PubMed ID: 30173534
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma.
Zhou JX; Li Y; Chen SX; Deng AM
J Exp Clin Cancer Res; 2011 Jan; 30(1):2. PubMed ID: 21211023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]